With the purpose of reducing side effects in anticancer therapy, the micelles of a novel reduction-activated copolymer with biomimicking phosphorylcholine, poly(ε-caprolactone)-ss-b-poly(2-methacryloyloxyethyl phosphorylcholine) (PCL-ss-PMPC) are developed. The well-suitable nanosize of micelles with good physiological stability (approximately 50 nm, 2.5 μg/mL) can be quickly internalized into cells due to bioinspired phosphorylcholine property and mainly located in endo/lysosomes. The reduction response of micelles is confirmed by size change and accelerated drug release under reducing environment, proved as better anticancer efficacy in comparison to insensitive micelles. Pharmacokinetics and in vivo studies demonstrate that redox-activated polymeric micelles can prolong blood transportation, facilitate passive target and accumulate in tumor site, and prompt drug release in cytoplasmic redox environment, behaving as much better antitumor efficiency than control and positive DOX·HCl groups. More importantly, the DOX-loaded micelles considerably reduce side effects and systematic toxicity. Therefore, this work fabricated an innovative bioinspired nanosystem via a facile strategy to achieve effective anticancer therapy.
Keywords: Anticancer drug delivery; Biomimicking; Phosphorylcholine; Reduction-activated.
Copyright © 2018. Published by Elsevier B.V.